{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:50Z","timestamp":1790706170286,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jaci.2011.06.010","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T09:14:11Z","timestamp":1311412451000},"page":"567-573.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":320,"title":["A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine\u2013refractory chronic idiopathic urticaria"],"prefix":"10.1016","volume":"128","author":[{"given":"Sarbjit","family":"Saini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Ju","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2011.06.010_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1398-9995.2009.02179.x","article-title":"EAACI\/GA(2)LEN\/EDF\/WAO guideline: definition, classification and diagnosis of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2011.06.010_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00130832-200310000-00008","article-title":"Chronic idiopathic urticaria","volume":"3","author":"Greaves","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2133.2005.06976.x","article-title":"Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity","volume":"154","author":"Staubach","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2011.06.010_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O\u2019Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2011.06.010_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1067\/mai.2002.126782","article-title":"Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity","volume":"110","author":"Sabroe","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2011.06.010_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2009.03256.x","article-title":"Pathogenesis of chronic urticaria","volume":"39","author":"Kaplan","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"suppl","key":"10.1016\/j.jaci.2011.06.010_bib8","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jaci.2007.12.398","article-title":"Immunoenzymetric assay measurement (IEMA) of autoantibodies in chronic idiopathic urticaria (CIU) in relation to basophil functional profile over time","volume":"121","author":"Eckman","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib9","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/jid.2008.416","article-title":"Independent evaluation of a commercial test for \u201cautoimmune\u201d urticaria in normal and chronic urticaria subjects","volume":"129","author":"Eckman","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2011.06.010_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1081-1206(10)60588-1","article-title":"Pathophysiology of chronic urticaria","volume":"100","author":"Brodell","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA(2)LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2011.06.010_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u201cidiopathic\u201d urticaria","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2011.06.010_bib14","series-title":"Xolair [prescribing information]","year":"2010"},{"key":"10.1016\/j.jaci.2011.06.010_bib15","unstructured":"Xolair: summary of product characteristics. European Medicines Agency; 2010. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000606\/WC500057298.pdf. Accessed June 23, 2011."},{"key":"10.1016\/j.jaci.2011.06.010_bib16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell FcepsilonRI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000250436","article-title":"Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy","volume":"151","author":"Oliver","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of omalizumab on patients with chronic urticaria","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1081-1206(10)60232-3","article-title":"Therapeutic alternatives for chronic urticaria: additional reports on omalizumab","volume":"101","author":"Spector","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl","key":"10.1016\/j.jaci.2011.06.010_bib22","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jaci.2007.12.1121","article-title":"Effect of Anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients","volume":"121","author":"Gober","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","article-title":"Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab","volume":"126","author":"Magerl","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1398-9995.2005.00964.x","article-title":"EAACI\/GA2LEN\/EDF guideline: definition, classification and diagnosis of urticaria","volume":"61","author":"Zuberbier","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2011.06.010_bib26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"Mlynek","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2011.06.010_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2011.06.010_bib28","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2011.06.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911009250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911009250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:31:20Z","timestamp":1758789080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674911009250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0091674911009250"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2011.06.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12016958.13148056","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.12016958.14782137","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine\u2013refractory chronic idiopathic urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2011.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}